FY2027 ICD-10-CM Update: New Codes for Hereditary Cancer Syndromes Take Effect October 1
Short answer: CMS's FY2027 ICD-10-CM update takes effect October 1, 2026, adding roughly 190 new diagnosis codes, retiring about 30 as no longer reportable, and revising four code titles. For the first time, Lynch syndrome, familial BRCA1/BRCA2 cancer, and Li-Fraumeni syndrome get their own dedicated codes instead of sharing the catch-all "genetic susceptibility to malignant neoplasm" code, Z15.09. Labs, genetic counselors, and ordering clinicians who bill hereditary-cancer testing have about a week left to update requisitions, EHR order sets, and payer-facing documentation before the switch.
What changes on October 1, and why genetic testing labs should care
Every October 1, CMS and the CDC's National Center for Health Statistics roll out a new annual ICD-10-CM code set, and the FY2027 cycle — covering encounters from October 1, 2026 through September 30, 2027 — is now final and posted to CMS's ICD-10 page. Two independent revenue-cycle publications, AGS Health and Nym Health, put the same headline numbers on the update: 190 new reportable diagnosis codes, 30 codes that are no longer valid for reporting, and four revised code titles.
Most annual ICD-10-CM cycles pass genetic testing labs by with barely a ripple — the bulk of new codes typically land in orthopedics, injury coding, or social determinants of health. This cycle is different. For the first time, hereditary cancer predisposition syndromes get carved out of the general genetic-susceptibility code block and given dedicated codes of their own, which is a meaningful change for any lab, genetic counselor, or ordering physician whose claims currently lean on that general-purpose code to document a positive Lynch syndrome, BRCA1/BRCA2, or Li-Fraumeni result.
From one catch-all code to dedicated hereditary cancer codes
Under the current FY2026 code set, a patient with a confirmed pathogenic BRCA1 mutation, a Lynch syndrome diagnosis, or Li-Fraumeni syndrome is typically documented with Z15.09, "genetic susceptibility to other malignant neoplasm" — a single, nonspecific code that has to stand in for dozens of distinct hereditary cancer syndromes with very different surveillance, management, and family-testing implications. Coding forums run by AAPC, the industry's largest medical coding credentialing body, show the recurring workaround: coders combining Z15.09 with a written diagnosis description just to make the specific syndrome legible on the claim.
According to AGS Health and Nym Health, the FY2027 update finally gives Lynch syndrome, familial cancer with a pathogenic BRCA1 or BRCA2 mutation, and Li-Fraumeni syndrome their own dedicated codes, "so inherited cancer risk can be documented explicitly rather than folded into a general family-history code," as AGS Health's coding team put it. The same update cycle also adds new dedicated codes for VEXAS syndrome and Loeys-Dietz syndrome — two rare genetic conditions that previously required nonspecific coding — and, per Nym Health, new codes covering inherited cardiomyopathies and arrhythmias. CMS has not published a plain-language summary of exact code numbers alongside the release; labs that need the specific new code strings for system builds should pull them directly from the official FY2027 addendum and conversion table on CMS's ICD-10 page rather than from secondary summaries, since exact code assignments were inconsistently reported across the trade coverage reviewed for this article.
The claims risk hiding in the 30 retired codes
New codes get the headlines, but the 30 codes losing reportable status on October 1 are where denials actually happen. As Nym Health's revenue-cycle analysis puts it, "a deleted code that still sits in a charge template, a payer policy, or a favorites list generates denials from day one." A code that was perfectly billable on September 30 can be rejected outright on October 1 if it wasn't swapped out of an EHR order set, a lab information system's test-to-diagnosis mapping, or a payer's own coverage policy language. For labs running high-throughput hereditary cancer panels, that risk compounds: a single stale code baked into an automated requisition template can generate a wave of same-cause denials before anyone notices the pattern.
This isn't a hypothetical. CMS's own FY2027 files, cited by both AGS Health and the American Health Care Association, explicitly warn that some previously billable codes are being demoted to non-billable category headers — meaning the parent code still exists in the classification but can no longer be submitted on a claim by itself. Coding teams that only check for outright code deletions, and not this quieter "no longer separately reportable" category, can miss exactly the kind of change most likely to slip through a mapping review.
What labs, ordering clinicians, and RCM teams should do before October 1
A short, focused review closes most of the exposure described above. Start by pulling every diagnosis code currently mapped to hereditary cancer test orders — Lynch syndrome, BRCA1/BRCA2, Li-Fraumeni, and any other syndrome-specific panel — out of requisition forms, EHR order sets, and lab information system test-to-diagnosis crosswalks, and check each one against the official FY2027 addendum rather than a summary article. Where Z15.09 has been used as a stand-in for one of these syndromes, confirm whether a more specific FY2027 code now applies and update default order-set logic accordingly, since payers increasingly expect the most specific code available rather than a general-purpose one.
Second, don't stop at checking for codes that were deleted outright — also check for codes CMS demoted to non-billable category headers, since those can look unchanged in a code list while quietly becoming unsubmittable. Third, cross-check any diagnosis codes embedded in payer medical policies or local coverage determinations that your lab bills against; a payer policy still written around a retired code creates a mismatch that can generate denials even after your own systems are updated. Finally, brief genetic counselors and ordering clinicians on the new hereditary-cancer-specific codes directly — more precise coding on the requisition reduces the number of queries and corrected claims RCM teams have to chase after the fact. Labs that already maintain a documented intake and coding workflow for hereditary cancer panels, the kind described in ScreenMyGene's guide to ICD-10 coding for genetic testing, have a natural checklist to run this update against rather than starting from scratch.
This update also lands alongside other coding and billing changes genetic testing labs are already tracking this year, including the DEX Z-code requirements now extending to commercial payers (see our recent coverage of DEX Z-codes and claim denials) and the broader pattern of claim denials tied to coding and documentation gaps (why genetic testing claims get denied). A missed ICD-10-CM update is one more entry on that same list, and one of the more preventable ones, since the effective date and general scope of the change have been public for weeks.
Frequently asked questions
When does the FY2027 ICD-10-CM update take effect?
October 1, 2026, for discharges and patient encounters occurring through September 30, 2027. CMS has already posted the final FY2027 files, including the code descriptions, addendum, and conversion table, to its ICD-10 page.
What is changing for hereditary cancer syndrome coding specifically?
Lynch syndrome, familial cancer with a pathogenic BRCA1 or BRCA2 mutation, and Li-Fraumeni syndrome move from sharing the general code Z15.09 to having their own dedicated codes, according to AGS Health and Nym Health's FY2027 update summaries. Exact new code numbers should be confirmed against CMS's official addendum before use in billing systems.
How many codes are being added or retired this cycle?
AGS Health and Nym Health both report approximately 190 new reportable diagnosis codes, 30 codes no longer valid for reporting, and four revised code titles for FY2027.
Why do retired codes matter if a lab isn't adding new diagnoses?
A code that loses reportable status, whether deleted outright or demoted to a non-billable category header, generates denials the moment it appears on a claim after October 1, even if nothing else about the claim changed. Codes embedded in EHR order sets, LIS mappings, or payer medical policies are the most common places a retired code keeps circulating unnoticed.
Are other genetic or hereditary conditions affected besides cancer syndromes?
Yes. The FY2027 cycle also adds dedicated codes for VEXAS syndrome and Loeys-Dietz syndrome and new codes covering inherited cardiomyopathies and arrhythmias, continuing a multi-year trend of ICD-10-CM adding specificity for genetic conditions that previously required nonspecific or workaround coding.
This article summarizes publicly available coding-update information as of September 2026 for general educational purposes. It is not billing, coding, legal, or medical advice. Exact FY2027 code numbers, effective dates for specific payers, and billing requirements should be verified directly against CMS's official ICD-10-CM files and each payer's current policy before use in any billing system or claim submission.
Sources: CMS.gov, "ICD-10" (official FY2027 code files); AGS Health, "FY 2027 ICD-10-CM Code Updates: What Coders And Revenue Cycle Teams Need To Know" (2026); Nym Health, "FY2027 ICD-10-CM Updates: What Revenue Cycle Teams Need to Know Before October 1" (2026); American Health Care Association / National Center for Assisted Living, "CMS Posts FY 2027 ICD-10-CM Update Effective Oct. 1" (2026); AAPC, ICD-10-CM code reference for Z15.09 ("Genetic susceptibility to other malignant neoplasm").